All lobbying filings

OGR

Lobbying for LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP · consulting firm on behalf of multi-sector collaboration of health care stakeholders

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 17, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

Michigan

Official filing document

Government bodies contacted 1

HOUSE OF REPRESENTATIVES

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.

Bills named in this filing 2

H.R. 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
H.R. 5178
Sickle Cell Disease Comprehensive Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.